Last reviewed · How we verify

Madrilenian Group of Cutaneous Lymphomas — Portfolio Competitive Intelligence Brief

Madrilenian Group of Cutaneous Lymphomas pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
PUVA (8MOP + UVA) + IFN PUVA (8MOP + UVA) + IFN marketed Photochemotherapy + cytokine combination Oncology
PUVA (8-MOP + UVA) PUVA (8-MOP + UVA) marketed Photochemotherapy agent DNA (non-specific cross-linking) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. M.D. Anderson Cancer Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Madrilenian Group of Cutaneous Lymphomas:

Cite this brief

Drug Landscape (2026). Madrilenian Group of Cutaneous Lymphomas — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/madrilenian-group-of-cutaneous-lymphomas. Accessed 2026-05-17.

Related